Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
101.20
-0.09 (-0.09%)
At close: Dec 1, 2025, 4:00 PM EST
101.11
-0.09 (-0.09%)
After-hours: Dec 1, 2025, 5:59 PM EST
Exact Sciences Revenue
Exact Sciences had revenue of $850.74M in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $3.08B, up 14.47% year-over-year. In the year 2024, Exact Sciences had annual revenue of $2.76B with 10.37% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+14.47%
P/S Ratio
6.16
Revenue / Employee
$440,290
Employees
7,000
Market Cap
19.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EXAS News
- 7 days ago - Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire
- 9 days ago - Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS - Business Wire
- 10 days ago - Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - Investopedia
- 11 days ago - Exact Sciences Corporation (EXAS) M&A Call Transcript - Seeking Alpha
- 11 days ago - Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More - The Motley Fool
- 11 days ago - Why Exact Sciences Rallied Over 50% This Week - The Motley Fool
- 11 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS) - GlobeNewsWire
- 11 days ago - Why Exact Sciences Stock Surged Today - The Motley Fool